TrialThoracic cancer2022

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).

Kazuhiro Asami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.